270 related articles for article (PubMed ID: 29939878)
1. Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.
Gutierrez C; McEvoy C; Mead E; Stephens RS; Munshi L; Detsky ME; Pastores SM; Nates JL
Crit Care Med; 2018 Sep; 46(9):1402-1410. PubMed ID: 29939878
[TBL] [Abstract][Full Text] [Related]
2. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
3. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
4. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill.
Suarez Montero JC; Caballero Gonzalez AC; Martín Aguilar L; Mancebo Cortés J
Med Intensiva (Engl Ed); 2022 Apr; 46(4):201-212. PubMed ID: 35216966
[TBL] [Abstract][Full Text] [Related]
5. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
Valand HA; Huda F; Tu RK
AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
Talleur AC; Myers R; Annesley C; Shalabi H
Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
9. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.
Bellal M; Malherbe J; Damaj G; Du Cheyron D
Crit Care; 2024 Mar; 28(1):69. PubMed ID: 38444031
[TBL] [Abstract][Full Text] [Related]
10. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
12. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
13. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
14. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity Biology and Management.
Danish H; Santomasso BD
Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
[TBL] [Abstract][Full Text] [Related]
18. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
Jamal FA; Khaled SK
Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
20. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
